Entera Bio Ltd
Company Profile
Business description
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Contact
Minrav Building - Fifth Floor
Kiryat Hadassah
Jerusalem9112002
ISRT: +972 25327151
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
20
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,826.70 | 48.80 | 0.56% |
CAC 40 | 7,929.78 | 51.32 | 0.65% |
DAX 40 | 24,583.92 | 34.36 | 0.14% |
Dow JONES (US) | 44,458.30 | 217.54 | 0.49% |
FTSE 100 | 8,958.20 | 91.18 | 1.03% |
HKSE | 24,028.37 | 136.05 | 0.57% |
NASDAQ | 20,611.34 | 192.87 | 0.94% |
Nikkei 225 | 39,646.36 | 174.92 | -0.44% |
NZX 50 Index | 12,760.20 | 8.41 | -0.07% |
S&P 500 | 6,263.26 | 37.74 | 0.61% |
S&P/ASX 200 | 8,589.20 | 50.60 | 0.59% |
SSE Composite Index | 3,509.68 | 16.63 | 0.48% |